Neumora Therapeutics (NMRA) Projected to Release Quarterly Earnings on Thursday

Key Points

• Neumora Therapeutics is expected to report Q3 2026 results before market open on November 5, with analysts forecasting a loss of $0.19 per share. The company previously reported a $0.23-per-share loss, beating estimates by $0.01.
• NMRA shares opened at $0.39 and remain near their one-year low of $0.32, with a market capitalization of approximately $73.9 million. Analysts project full-year and next-year losses of $0.83 and $0.69 per share, respectively.
• Analyst sentiment is mixed but averages a “Moderate Buy” rating with a consensus price target of $6.57. Insiders have sold 453,833 shares worth about $701,000 over the past three months, while the company continues developing brain-disease treatments including navacaprant.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) is anticipated to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Neumora Therapeutics to announce earnings of ($0.19) per share for the quarter. Individuals are encouraged to explore the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.01. On average, analysts expect Neumora Therapeutics to post ($0.83) EPS for the current fiscal year and ($0.69) EPS for the next fiscal year.

Neumora Therapeutics Trading Up 6.8%

Shares of NMRA stock opened at $0.39 on Thursday. The company has a debt-to-equity ratio of 1.19, a current ratio of 4.50 and a quick ratio of 4.50. The firm has a market cap of $73.86 million, a PE ratio of -0.32 and a beta of 2.95. The company has a 50-day moving average of $0.84 and a two-hundred day moving average of $1.80. Neumora Therapeutics has a 1-year low of $0.32 and a 1-year high of $3.65.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings raised shares of Neumora Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, September 25th. Royal Bank Of Canada lowered their price objective on shares of Neumora Therapeutics from $7.00 to $5.00 and set an "outperform" rating for the company in a research report on Monday, July 13th. HC Wainwright reiterated a "buy" rating on shares of Neumora Therapeutics in a report on Tuesday, July 28th. Finally, Wall Street Zen downgraded shares of Neumora Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, October 10th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $6.57.

Insider Buying and Selling

In other Neumora Therapeutics news, insider Daljit Singh Aurora sold 91,690 shares of Neumora Therapeutics stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1.50, for a total value of $137,535.00. Following the completion of the transaction, the insider directly owned 48,750 shares of the company's stock, valued at $73,125. The trade was a 65.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last three months, insiders sold 453,833 shares of company stock worth $701,219. Company insiders own 26.94% of the company's stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases. The company combines neuroscience, data science and machine-learning technologies to identify disease mechanisms, discover potential therapies and develop more targeted medicines for patients with neurological and neuropsychiatric disorders.

Neumora's pipeline has included navacaprant, also known as NMRA-140, an investigational selective kappa opioid receptor antagonist being studied for major depressive disorder and related symptoms such as anhedonia, or the loss of interest and pleasure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.